5.089
4.41%
0.214
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IBRX Giù?
Forum
Previsione
Immunitybio Inc Azioni (IBRX) Dati Finanziari
Conto economico
Trimestrale
*Tutti i numeri sono espressi in milioni
Data di fine periodo | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 |
Durata del periodo | 3 mesi | 3 mesi | 3 mesi | 3 mesi | 3 mesi |
Revenues |
71.22%
0.04
|
0.139 | 0.082 | 0.041 | 0.36 |
Operating Expenses
|
11.35%
95.24
|
85.53 | 80.22 | 85.19 | 111.94 |
Interest Income/Expense |
8.23%
29.48
|
32.13 | 35.02 | 32.23 | 29.82 |
Benefits Costs and Expenses |
42.56%
134.17
|
233.59 | 95.72 | 138.25 | 116.94 |
Costs And Expenses |
42.56%
134.17
|
233.59 | 95.72 | 138.25 | 116.94 |
Operating Income/Loss |
11.49%
-95.20
|
-85.39 | -80.14 | -85.14 | -111.58 |
Nonoperating Income/Loss |
73.70%
-38.93
|
-148.06 | -15.51 | -53.07 | -5.003 |
Income/Loss From Equity Method Investments |
-
|
- | -1.255 | -3.957 | -2.337 |
Income/Loss From Continuing Operations Before Tax |
42.55%
-134.13
|
-233.45 | -95.64 | -138.21 | -116.58 |
Income Tax Expense/Benefit |
100.00%
-
|
-0.04 | - | - | - |
Income/Loss From Continuing Operations After Tax |
42.54%
-134.13
|
-233.41 | -95.64 | -138.21 | -116.58 |
Net Income/Loss
|
42.54%
-134.13
|
-233.41 | -95.64 | -138.21 | -116.58 |
Preferred Stock Dividends And Other Adjustments |
-
|
- | - | - | - |
Attributable To Noncontrolling Interest |
4.55%
-0.021
|
-0.022 | -0.06 | -0.334 | -0.24 |
Basic Average Shares |
1,154%
672.83
|
53.64 | 498.38 | 437.46 | 428.38 |
Diluted Average Shares |
1,154%
672.83
|
53.64 | 498.38 | 437.46 | 428.38 |
Basic Earnings Per Share |
47.37%
-0.20
|
-0.38 | -0.19 | -0.32 | -0.27 |
Diluted Earnings Per Share |
47.37%
-0.20
|
-0.38 | -0.19 | -0.32 | -0.27 |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic |
-
|
- | - | - | - |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):